Correction made on the Company’s Consolidation Financial Report for the Q1 2022 filled to the Mops

 Correction made on the Company's Consolidation
Financial Report for the Q1 2022 filled to the Mops

1.Date of occurrence of the event:2022/06/08
2.Company name:Center Laboratories, Inc.
3.Relationship to the Company (please enter "head
  office" or  "subsidiaries"):Head office
4.Reciprocal shareholding ratios:NA
5.Cause of occurrence:
Newly added notes to the Administrative Expenses from Consolidated of
Comprehensive Income Statement of the Company's Q1 2022 Consolidated
Financial Report
6.Information items/ statements to be corrected:
On P7 Consolidated of Comprehensive Income Statement and P35 item 六.15
Provision on Debts
7.Amounts/ contents/ number of page to be corrected:
P7 Administrative Expenses Unannotated
8.Amounts/ contents/ number of page after correction:
(1) Added notes 六.15 to P7 Administrative Expenses
(2) Newly added illustration on P35 item 六.15 Provision on Debts
9.Countermeasures:
In Q1 2022, the market price of listed OTC stocks which held by Bioengine
Capital Inc. fell. According to the management agreement, recalculating
the performance bonus that was book as a debt reserve; simultaneously,
reduced the amount of debt reserve and write down 175,7000 thousand of
Administrative Expense (for Performance Bonus). Consequently, lead to
a negative Administrative Expense under Operating Expense on Q1 2022
Consolidated Income Statement
10.Any other matters that need to be specified:None.